A detailed history of Raymond James & Associates transactions in Amneal Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 161,380 shares of AMRX stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
161,380
Previous 162,125 0.46%
Holding current value
$1.27 Million
Previous $1.03 Million 30.42%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$6.42 - $8.83 $4,782 - $6,578
-745 Reduced 0.46%
161,380 $1.34 Million
Q2 2024

Jul 19, 2024

SELL
$5.36 - $7.11 $15,881 - $21,066
-2,963 Reduced 1.79%
162,125 $1.03 Million
Q1 2024

Apr 22, 2024

BUY
$5.24 - $6.34 $18,083 - $21,879
3,451 Added 2.14%
165,088 $1 Million
Q4 2023

Jan 16, 2024

SELL
$3.36 - $6.21 $66,360 - $122,647
-19,750 Reduced 10.89%
161,637 $981,000
Q3 2023

Oct 24, 2023

BUY
$2.76 - $4.59 $55,199 - $91,800
20,000 Added 12.39%
181,387 $765,000
Q3 2022

Oct 25, 2022

SELL
$2.02 - $3.62 $9,263 - $16,601
-4,586 Reduced 2.76%
161,387 $326,000
Q2 2022

Aug 12, 2022

SELL
$3.01 - $4.46 $6,020 - $8,920
-2,000 Reduced 1.19%
165,973 $528,000
Q1 2022

May 11, 2022

SELL
$3.9 - $4.89 $17,550 - $22,005
-4,500 Reduced 2.61%
167,973 $700,000
Q4 2021

Feb 08, 2022

SELL
$3.95 - $5.85 $10,187 - $15,087
-2,579 Reduced 1.47%
172,473 $826,000
Q3 2021

Nov 02, 2021

BUY
$4.31 - $5.64 $8,620 - $11,280
2,000 Added 1.16%
175,052 $935,000
Q2 2021

Aug 11, 2021

BUY
$5.12 - $6.82 $15,360 - $20,460
3,000 Added 1.76%
173,052 $886,000
Q1 2021

May 14, 2021

SELL
$4.74 - $7.38 $18,803 - $29,276
-3,967 Reduced 2.28%
170,052 $1.14 Million
Q4 2020

Feb 12, 2021

SELL
$3.95 - $5.42 $829 - $1,138
-210 Reduced 0.12%
174,019 $795,000
Q3 2020

Nov 04, 2020

BUY
$3.54 - $5.27 $22,886 - $34,070
6,465 Added 3.85%
174,229 $676,000
Q2 2020

Jul 28, 2020

BUY
$2.87 - $5.46 $717 - $1,365
250 Added 0.15%
167,764 $799,000
Q1 2020

Apr 21, 2020

BUY
$2.46 - $5.35 $91,020 - $197,950
37,000 Added 28.35%
167,514 $583,000
Q4 2019

Feb 12, 2020

BUY
$2.65 - $5.56 $87,132 - $182,812
32,880 Added 33.68%
130,514 $629,000
Q3 2019

Nov 07, 2019

BUY
$2.29 - $7.1 $123,524 - $382,981
53,941 Added 123.45%
97,634 $283,000
Q2 2019

Aug 06, 2019

BUY
$6.44 - $14.29 $37,345 - $82,867
5,799 Added 15.3%
43,693 $313,000
Q1 2019

May 06, 2019

SELL
$11.87 - $14.84 $107,316 - $134,168
-9,041 Reduced 19.26%
37,894 $537,000
Q4 2018

Feb 11, 2019

SELL
$13.09 - $21.49 $155,247 - $254,871
-11,860 Reduced 20.17%
46,935 $635,000
Q3 2018

Nov 14, 2018

BUY
$16.4 - $24.27 $243,277 - $360,021
14,834 Added 33.74%
58,795 $1.31 Million
Q2 2018

Aug 14, 2018

BUY
$13.95 - $20.2 $613,255 - $888,012
43,961 New
43,961 $721,000

Others Institutions Holding AMRX

About Amneal Pharmaceuticals, Inc.


  • Ticker AMRX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 151,408,992
  • Market Cap $1.19B
  • Description
  • Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and comme...
More about AMRX
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.